Loading clinical trials...
Loading clinical trials...
A Prospective, Multicenter, Postmarket Study of Sebacia Microparticles Treatment in Patients Using Topical Acne Products for Mild to Moderate Inflammatory Acne Vulgaris
Conditions
Interventions
Sebacia Microparticles Treatment
Locations
6
United States
Miami Dermatology & Laser Institute
Miami, Florida, United States
Dermatology Institute of Boston
Boston, Massachusetts, United States
International Clinical Research
Murfreesboro, Tennessee, United States
Austin Institute for Clinical Research - Central
Austin, Texas, United States
Austin Institute for Clinical Research - Pflugerville
Pflugerville, Texas, United States
Premier Clinical Research
Spokane, Washington, United States
Start Date
January 1, 2019
Primary Completion Date
June 1, 2021
Completion Date
June 1, 2021
Last Updated
October 27, 2020
NCT07205107
NCT05891795
NCT06501560
NCT03883269
NCT07469228
NCT07348978
Lead Sponsor
Sebacia, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions